NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis $2.39 -0.04 (-1.65%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.36▼$2.4750-Day Range$2.39▼$3.4952-Week Range$2.36▼$6.05Volume1.83 million shsAverage Volume1.56 million shsMarket Capitalization$702.79 millionP/E RatioN/ADividend YieldN/APrice Target$14.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AbCellera Biologics alerts: Email Address AbCellera Biologics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside494.1% Upside$14.20 Price TargetShort InterestBearish8.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.55) to ($0.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector623rd out of 910 stocksPharmaceutical Preparations Industry285th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingAbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAbCellera Biologics has only been the subject of 2 research reports in the past 90 days.Read more about AbCellera Biologics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.79% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in AbCellera Biologics has recently increased by 4.31%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCL. Previous Next 2.0 News and Social Media Coverage News SentimentAbCellera Biologics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.Search InterestOnly 19 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -36% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbCellera Biologics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.55) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about AbCellera Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About AbCellera Biologics Stock (NASDAQ:ABCL)AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Read More ABCL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCL Stock News HeadlinesSeptember 6 at 2:17 AM | americanbankingnews.comAbCellera Biologics Inc. (NASDAQ:ABCL) Receives $14.20 Average Price Target from BrokeragesSeptember 2, 2024 | finance.yahoo.comAbCellera Biologics Inc. (ABCL): The Best Multibagger Penny Stock of 2025?September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 1, 2024 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Up to $2.53August 31, 2024 | finance.yahoo.comCarl Hansen Buys Handful Of Shares In AbCellera BiologicsAugust 30, 2024 | msn.comAbCellera Biologics Inc. (ABCL): A Top Contender Among Canada’s Best Penny Stocks in 2024August 30, 2024 | finance.yahoo.comAbCellera to Present at Upcoming Investor Conferences in SeptemberAugust 29, 2024 | msn.comAbCellera Biologics Inc. (ABCL): A Top Contender Among Canada's Best Penny Stocks in 2024September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 23, 2024 | markets.businessinsider.comKeyBanc Keeps Their Buy Rating on AbCellera Biologics (ABCL)August 23, 2024 | seekingalpha.comAbCellera: A Waiting Game With High UncertaintyAugust 21, 2024 | msn.comBenchmark Downgrades AbCellera Biologics (ABCL)August 17, 2024 | ca.finance.yahoo.comABCL Sep 2024 2.000 callAugust 11, 2024 | finance.yahoo.comNeed To Know: The Consensus Just Cut Its AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates For 2024August 9, 2024 | markets.businessinsider.comStrong Liquidity and Strategic Alliances Underpin Buy Rating for AbCellera BiologicsAugust 9, 2024 | finance.yahoo.comEarnings Update: AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Are Trimming Their ForecastsAugust 8, 2024 | investing.comAbcellera Biologics earnings beat, revenue fell short of estimatesAugust 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for AbCellera Biologics Amid Expanding TCE Program and Strengthened Eli Lilly CollaborationSee More Headlines Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABCL CUSIPN/A CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees586Year FoundedN/APrice Target and Rating Average Stock Price Target$14.20 High Stock Price Target$20.00 Low Stock Price Target$5.00 Potential Upside/Downside+494.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,400,000.00 Net Margins-463.77% Pretax Margin-540.95% Return on Equity-13.40% Return on Assets-10.44% Debt Debt-to-Equity RatioN/A Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$33.05 million Price / Sales21.26 Cash FlowN/A Price / Cash FlowN/A Book Value$3.77 per share Price / Book0.63Miscellaneous Outstanding Shares294,054,000Free Float198,633,000Market Cap$702.79 million OptionableOptionable Beta0.37 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Carl L.G. Hansen Ph.D. (Age 49)CEO, President & Chairperson Comp: $711.47kMr. Andrew Booth M.B.A. (Age 50)Chief Financial Officer Comp: $642.42kDr. Veronique Lecault Ph.D. (Age 39)COO & Director Comp: $645.07kMr. Tryn T. Stimart Esq. (Age 54)J.D., M.Sc., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Comp: $644.4kMr. Neil Aubuchon B.A. (Age 53)M.B.A., Chief Commercial Officer Comp: $684.81kMarcie Thiessen CPACGA, Senior Director of Finance & AccountingDr. Ester Falconer Ph.D. (Age 49)Chief Technology Officer Kathleen Reid B.A.Head of Corporate CommunicationsGraham Craig M.Sc.Director of Corporate DevelopmentMr. Murray McCutcheon Ph.D.Senior Vice President of PartneringMore ExecutivesKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRIDEAYA BiosciencesNASDAQ:IDYAACADIA PharmaceuticalsNASDAQ:ACADAmneal PharmaceuticalsNASDAQ:AMRXGeronNASDAQ:GERNView All CompetitorsInstitutional OwnershipSanctuary Advisors LLCBought 105,924 shares on 9/5/2024Ownership: 0.036%B. Riley Wealth Advisors Inc.Bought 11,000 shares on 8/19/2024Ownership: 0.007%Dark Forest Capital Management LPBought 45,721 shares on 8/15/2024Ownership: 0.050%Squarepoint Ops LLCBought 22,132 shares on 8/14/2024Ownership: 0.023%Evergreen Capital Management LLCBought 10,685 shares on 8/14/2024Ownership: 0.004%View All Institutional Transactions ABCL Stock Analysis - Frequently Asked Questions How have ABCL shares performed this year? AbCellera Biologics' stock was trading at $5.71 on January 1st, 2024. Since then, ABCL stock has decreased by 58.1% and is now trading at $2.39. View the best growth stocks for 2024 here. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. The firm's revenue was down 27.7% compared to the same quarter last year. When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $356 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? AbCellera Biologics' top institutional investors include Baillie Gifford & Co. (7.45%), Federated Hermes Inc. (0.93%), Renaissance Technologies LLC (0.59%) and Intellectus Partners LLC (0.19%). Insiders that own company stock include Holdings Ltd Thermopylae, Veronique Lecault, Andrew Booth, Andrew Lo and John S Montalbano. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABCL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
